1.
Self Selection of P
medicines – The Journey

2.
What we proposed and why
• Outcome focussed standards
• No one size fits all approach
• Encourages joint decision making and meaningful
discussion
• Legal framework remains
• Enables tailored service provision
Therefore, the draft standards did not contain a
prescriptive prohibition

3.
What we have heard
For (enabling self selection) Against (enabling self selection)
• Should be safe to rely on the professional • Medicines are not ordinary items of
judgement of pharmacists who decide what commerce
medicines should be on display
• Cost and time benefit • High risk, theft
• Reflects that one size doesn’t fit all • Erosion of the P category
• Supports informed decision making • GPhC not carrying out its role in protecting
patient safety + public interest
• Encourages collaboration and dialogue • Commercial managers will use the changes
to ‘market’ P medicines more aggressively
• Introduce inconsistencies in the availability
of medicines – confusing

4.
Our proposals
• No prescriptive statement in standards
• Draft compliance guidance
• Compliance guidance subject to consultation and
published early 2013
• Until publication of compliance guidance –
prohibition on self selection remains
Next steps
• Draft compliance guidance

5.
Discussion
• Are you content with the proposals?
• What risks, if any, do you think we need
to address?
• In addition to compliance guidance, what
other mechanisms can we use to manage
these?